AR066691A1 - Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. - Google Patents
Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas.Info
- Publication number
- AR066691A1 AR066691A1 ARP080101259A ARP080101259A AR066691A1 AR 066691 A1 AR066691 A1 AR 066691A1 AR P080101259 A ARP080101259 A AR P080101259A AR P080101259 A ARP080101259 A AR P080101259A AR 066691 A1 AR066691 A1 AR 066691A1
- Authority
- AR
- Argentina
- Prior art keywords
- alkyl
- alkylcarbonyl
- alkylamino
- mono
- alkylcarbonylamino
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/12—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains three hetero rings
- C07D491/20—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4164—1,3-Diazoles
- A61K31/4188—1,3-Diazoles condensed with other heterocyclic ring systems, e.g. biotin, sorbinil
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P11/00—Drugs for disorders of the respiratory system
- A61P11/16—Central respiratory analeptics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P27/00—Drugs for disorders of the senses
- A61P27/02—Ophthalmic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/04—Anorexiants; Antiobesity agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/12—Drugs for disorders of the metabolism for electrolyte homeostasis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/38—Drugs for disorders of the endocrine system of the suprarenal hormones
- A61P5/42—Drugs for disorders of the endocrine system of the suprarenal hormones for decreasing, blocking or antagonising the activity of mineralocorticosteroids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/02—Antithrombotic agents; Anticoagulants; Platelet aggregation inhibitors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/04—Inotropic agents, i.e. stimulants of cardiac contraction; Drugs for heart failure
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/06—Antiarrhythmics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Cardiology (AREA)
- Diabetes (AREA)
- Heart & Thoracic Surgery (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Child & Adolescent Psychology (AREA)
- Vascular Medicine (AREA)
- Hospice & Palliative Care (AREA)
- Pain & Pain Management (AREA)
- Rheumatology (AREA)
- Ophthalmology & Optometry (AREA)
- Pulmonology (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
Abstract
Uso de estos compuestos como medicamentos, en particular, como inhibidores de la aldosterona sintasa. Reivindicacion 1: Un compuesto de la formula general (1): donde Q es -C(R3)(R4)- o un enlace; T es -(CR3)(R4)-, R es hidrogeno o deuterio; R1 es alquilo C1-8, alquilcarbonilo C0-8, amino, mono- o di-alquilamino C1-8, alquilcarbonilamino C0-8, alquilcarbonilo C0-8-alquilamino C1-8, carbamoilo, mono- o di-alquilaminocarbonilo C1-8, carboxilo, carboxi-alquilo C1-4, halogeno, ciano, metilsulfonilo, nitro, trifluormetilo, alcoxi C1-8, alcoxicarbonilo C1-8, heterociclilo o arilo, donde dichos radicales pueden estar no sustituidos o sustituidos con 1-4 alquilo C1-8, alquilcarbonilo C0-8, halogeno, ciano, oxo, trifluormetilo, trifluormetoxi, alquilcarbonilamino C0-8, alquilcarbonilo C0-8-alquilamino C1-8, carbamoilo, mono- y di-alquilaminocarbonilo C1-8, carboxi-alquilo C0-4, alcoxi C1-8, alcoxicarbonilo C1-8, arilo o heterociclilo; R2 es, si p no es 0, independientemente entre sí, alquilo C1-8, alquilcarbonilo C0-8, amino, mono- y di-alquilamino C1-8, alquilcarbonilamino C0-8, alquilcarbonilo C0-8-alquilamino C1-8, carbamoilo, mono- o dialquilaminocarbonilo C1-8, carboxilo, carboxi-alquilo C1-4, halogeno, ciano, metilsulfonilo, nitro, trifluormetilo, trifluormetoxi, alcoxi C1-8, alcoxicarbonilo C1-8, heterociclilo o arilo, donde dichos radicales pueden estar no sustituidos o sustituidos con 1-4 alquilo C1-8, alquilcarbonilo C0-8, halogeno, ciano, oxo, trifluormetilo, trifluormetoxi, alquilcarbonilamino C0-8, alquilcarbonilo C0-8-alquilamino C1-8, carbamoílo, mono- y di-alquilaminocarbonilo C1-8, carboxialquilo C0-4, alcoxi C1-8, alcoxicarbonilo C1-8, arilo o heterociclilo; R3 es, de manera independiente entre sí: a) hidrogeno o alquilo C1-8, o b) junto con R4, oxo; R4 es, de manera independiente entre sí: a) hidrogeno o alquilo C1-8, o b) junto con R3, oxo; n es un numero 0, 1 o 2; p es un numero 0, 1 o 2; o su sal, preferentemente, su sal farmacéuticamente util.
Applications Claiming Priority (1)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP07105246 | 2007-03-29 |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| AR066691A1 true AR066691A1 (es) | 2009-09-09 |
Family
ID=38461947
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| ARP080101259A AR066691A1 (es) | 2007-03-29 | 2008-03-27 | Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. |
Country Status (18)
| Country | Link |
|---|---|
| US (1) | US8324235B2 (es) |
| EP (1) | EP2134720B1 (es) |
| JP (1) | JP5331789B2 (es) |
| KR (1) | KR20090126310A (es) |
| CN (1) | CN101711252A (es) |
| AR (1) | AR066691A1 (es) |
| AT (1) | ATE484507T1 (es) |
| AU (1) | AU2008234957A1 (es) |
| BR (1) | BRPI0809645A2 (es) |
| CA (1) | CA2681978A1 (es) |
| DE (1) | DE602008003015D1 (es) |
| ES (1) | ES2354008T3 (es) |
| MX (1) | MX2009008264A (es) |
| PL (1) | PL2134720T3 (es) |
| PT (1) | PT2134720E (es) |
| RU (1) | RU2009139811A (es) |
| TW (1) | TW200904416A (es) |
| WO (1) | WO2008119744A1 (es) |
Families Citing this family (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2009151069A1 (ja) | 2008-06-12 | 2009-12-17 | 第一三共株式会社 | ４，７－ジアザスピロ［２．５］オクタン環構造を有するイミダゾチアゾール誘導体 |
| EA201101672A1 (ru) | 2009-05-28 | 2012-06-29 | Новартис Аг | Замещенные производные аминомасляной кислоты в качестве ингибиторов неприлизина |
| AU2010251967B9 (en) | 2009-05-28 | 2014-04-03 | Novartis Ag | Substituted aminopropionic derivatives as neprilysin inhibitors |
| KR20120065311A (ko) | 2009-07-15 | 2012-06-20 | 씬산 강 | 저산소증 모방체인 화합물, 및 그의 조성물 및 용도 |
| JO2967B1 (en) | 2009-11-20 | 2016-03-15 | نوفارتس ايه جي | Acetic acid derivatives of carbamoyl methyl amino are substituted as new NEP inhibitors |
| US8673974B2 (en) | 2010-11-16 | 2014-03-18 | Novartis Ag | Substituted amino bisphenyl pentanoic acid derivatives as NEP inhibitors |
| US8877815B2 (en) | 2010-11-16 | 2014-11-04 | Novartis Ag | Substituted carbamoylcycloalkyl acetic acid derivatives as NEP |
| CA2841117A1 (en) | 2011-07-08 | 2013-01-17 | Novartis Ag | 1,2-disubstituted-4-benzylamino-piperidinyl derivatives as cetp inhibitors useful for the treatment of atherosclerosis in high triglyceride subjects |
| EP2567959B1 (en) | 2011-09-12 | 2014-04-16 | Sanofi | 6-(4-hydroxy-phenyl)-3-styryl-1h-pyrazolo[3,4-b]pyridine-4-carboxylic acid amide derivatives as kinase inhibitors |
| UY35144A (es) | 2012-11-20 | 2014-06-30 | Novartis Ag | Miméticos lineales sintéticos de apelina para el tratamiento de insuficiencia cardiaca |
| PE20151666A1 (es) | 2013-02-14 | 2015-11-19 | Novartis Ag | Derivados sustituidos del acido bisfenil butanoico fosfonico como inhibidores de la nep |
| CN105612172A (zh) | 2013-07-25 | 2016-05-25 | 诺华股份有限公司 | 用于治疗心力衰竭的环状多肽 |
| PE20160991A1 (es) | 2013-07-25 | 2016-10-15 | Novartis Ag | Bioconjugados de polipeptidos de apelina sintetica |
| BR112017014194A2 (pt) | 2015-01-23 | 2018-01-09 | Novartis Ag | conjugados de ácido graxo de apelina sintéticos com meia-vida melhorada |
| SG11201810847RA (en) * | 2016-06-10 | 2019-01-30 | Nihon Mediphysics Co Ltd | Non-invasive diagnostic imaging agent for heart disease |
| JOP20190086A1 (ar) | 2016-10-21 | 2019-04-18 | Novartis Ag | مشتقات نافثيريدينون جديدة واستخدامها في معالجة عدم انتظام ضربات القلب |
| WO2019023264A1 (en) * | 2017-07-25 | 2019-01-31 | The Board Of Trustees Of The Leland Stanford Junior University | MODULATING AGENTS OF GLUCOSE-6-PHOSPHATE DEHYDROGENASE (G6PD) AND METHODS OF TREATING A G6PD DEFICIT |
| UY38072A (es) | 2018-02-07 | 2019-10-01 | Novartis Ag | Compuestos derivados de éster butanoico sustituido con bisfenilo como inhibidores de nep, composiciones y combinaciones de los mismos |
| UY38485A (es) | 2018-11-27 | 2020-06-30 | Novartis Ag | Compuestos tetrámeros cíclicos como inhibidores de proproteína convertasa subtilisina/kexina tipo 9 (pcsk9), método de tratamiento, uso y su preparación |
| EP3887363A1 (en) | 2018-11-27 | 2021-10-06 | Novartis AG | Cyclic pentamer compounds as proprotein convertase subtilisin/kexin type 9 (pcsk9) inhibitors for the treatment of metabolic disorder |
| CN113166204A (zh) | 2018-11-27 | 2021-07-23 | 诺华股份有限公司 | 作为治疗代谢障碍的蛋白质原转换酶枯草杆菌蛋白酶/kexin 9型（PCSK9）抑制剂的环状肽 |
| WO2023084449A1 (en) | 2021-11-12 | 2023-05-19 | Novartis Ag | Diaminocyclopentylpyridine derivatives for the treatment of a disease or disorder |
| AR127698A1 (es) | 2021-11-23 | 2024-02-21 | Novartis Ag | Derivados de naftiridinona para el tratamiento de una enfermedad o un trastorno |
Family Cites Families (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW200716636A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
| TW200716634A (en) * | 2005-05-31 | 2007-05-01 | Speedel Experimenta Ag | Heterocyclic spiro-compounds |
-
2008
- 2008-03-27 RU RU2009139811/04A patent/RU2009139811A/ru not_active Application Discontinuation
- 2008-03-27 AU AU2008234957A patent/AU2008234957A1/en not_active Abandoned
- 2008-03-27 JP JP2010500283A patent/JP5331789B2/ja not_active Expired - Fee Related
- 2008-03-27 EP EP08735533A patent/EP2134720B1/en not_active Not-in-force
- 2008-03-27 MX MX2009008264A patent/MX2009008264A/es active IP Right Grant
- 2008-03-27 CA CA002681978A patent/CA2681978A1/en not_active Abandoned
- 2008-03-27 TW TW097110903A patent/TW200904416A/zh unknown
- 2008-03-27 BR BRPI0809645-7A patent/BRPI0809645A2/pt not_active IP Right Cessation
- 2008-03-27 WO PCT/EP2008/053671 patent/WO2008119744A1/en active Application Filing
- 2008-03-27 AR ARP080101259A patent/AR066691A1/es unknown
- 2008-03-27 US US12/450,521 patent/US8324235B2/en not_active Expired - Fee Related
- 2008-03-27 KR KR1020097022483A patent/KR20090126310A/ko not_active Application Discontinuation
- 2008-03-27 PT PT08735533T patent/PT2134720E/pt unknown
- 2008-03-27 CN CN200880010854A patent/CN101711252A/zh active Pending
- 2008-03-27 AT AT08735533T patent/ATE484507T1/de active
- 2008-03-27 ES ES08735533T patent/ES2354008T3/es active Active
- 2008-03-27 PL PL08735533T patent/PL2134720T3/pl unknown
- 2008-03-27 DE DE602008003015T patent/DE602008003015D1/de active Active
Also Published As
| Publication number | Publication date |
|---|---|
| CA2681978A1 (en) | 2008-10-09 |
| US8324235B2 (en) | 2012-12-04 |
| JP2010522725A (ja) | 2010-07-08 |
| RU2009139811A (ru) | 2011-05-10 |
| TW200904416A (en) | 2009-02-01 |
| EP2134720A1 (en) | 2009-12-23 |
| EP2134720B1 (en) | 2010-10-13 |
| WO2008119744A1 (en) | 2008-10-09 |
| ES2354008T3 (es) | 2011-03-09 |
| US20100144774A1 (en) | 2010-06-10 |
| DE602008003015D1 (de) | 2010-11-25 |
| MX2009008264A (es) | 2009-08-12 |
| PT2134720E (pt) | 2010-12-07 |
| BRPI0809645A2 (pt) | 2014-09-23 |
| KR20090126310A (ko) | 2009-12-08 |
| JP5331789B2 (ja) | 2013-10-30 |
| PL2134720T3 (pl) | 2011-04-29 |
| CN101711252A (zh) | 2010-05-19 |
| ATE484507T1 (de) | 2010-10-15 |
| AU2008234957A1 (en) | 2008-10-09 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| AR066691A1 (es) | Compuestos espiro heterociclicos derivados de imidazol. composiciones farmaceuticas. | |
| AR060591A1 (es) | Compuestos imidazo | |
| AR054369A1 (es) | Compuestos de imidazol condensado y su uso como inhibidores de aldosterona sintasa | |
| AR060590A1 (es) | Compuestos imidazo | |
| AR056888A1 (es) | Derivados de heterociclil imidazol | |
| CO6241190A2 (es) | Compuestos para inhibicion enzimatica | |
| CO6331437A2 (es) | Compuestos de pirrolo[2,3-d]pirimidina | |
| ES2422204T3 (es) | Novedosos derivados de imidazolidin-2-ona como moduladores selectivos de receptor de andrógenos (SARMS) | |
| EA200970207A1 (ru) | Соединения пиридо[2,3-d]пиримидинона и их применение в качестве pi3 ингибиторов | |
| ECSP034865A (es) | Resolución óptica de (1-benzilo-4-metilopiperidina-3-il)-metilamina y su uso para la preparación de derivados de pirrolo 2,3-pirimidina como inhibidores de proteina quinasas | |
| AR053739A1 (es) | Compuestos espiro condensados como inhibidores de la aldosterona sintasa | |
| MA39211B1 (fr) | Composés tricycliques comme agents anti-cancers | |
| AR044519A1 (es) | Derivados de piridin-tiazol amina y de pirimidin-tiazol amina | |
| NO20070122L (no) | Quinazolinonderivater anvendelige som vanilloidantagonister | |
| TW200720266A (en) | Benzodioxane and benzodioxolan derivatives and uses thereof | |
| AR067443A1 (es) | Derivados heterociclicos de n-benziloxazolidinonas potenciadores de receptores de glutamato mglur2, composiciones farmaceuticas que los contienen y usos de los mismos en el tratamiento de trastornos del sistema nervioso central | |
| NO20072235L (no) | HCV-hemmende bicykliske pyrimidiner | |
| AR071236A1 (es) | Inhibidores ciclicos de la 11beta-hidroxiesteroide deshidrogenasa 1 | |
| BRPI0418639B8 (pt) | compostos inibidores de dipeptidil peptidase, assim como composição farmacêutica contendo os mesmos | |
| AR057040A1 (es) | Compuestos espiro heterociclicos y composicion farmaceutica | |
| EA201070395A1 (ru) | Ингибиторы polo-подобных киназ | |
| DK1753723T3 (da) | Substituerede quinolinderivater som mitotiske kinesininhibitorer | |
| EA200970041A1 (ru) | Ингибиторы акт (протеинкиназы в) | |
| HK1133012A1 (en) | Pyrimidinones as casein kinase ii (ck2) modulators | |
| RS53341B (en) | CIS-TETRAHYDRO-SPIRO DERIVATIVES (CYCLOHEXAN-1,1`-PYRIDO [3,4-B] INDOL) -4-AMINE |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| FB | Suspension of granting procedure |